Sareum Regulatory News (SAR)

Sareum Holdings plc

("Sareum" or the "Company")

Patent Allowance for Crystalline Forms of SDC-1801 in China

Cambridge, UK, 16 September 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce that it has received a Notice of Allowance from the China National Intellectual Property Administration. This notice pertains to a patent application protecting certain crystalline forms of SDC-1801, a dual TYK2/JAK1 kinase inhibitor being developed as a potential new therapeutic for a wide range of autoimmune diseases.

The Chinese patent, application number 2021800259993, will provide significant protection on several crystalline forms of SDC-1801 and in the methods of their preparation. The Company anticipates the Chinese patent to be granted by the end of 2024, subject to the fulfilment of certain formalities. This is the first patent allowance protecting crystalline forms of SDC-1801 in any territory. Patent applications in other key territories, including the US, Europe, Japan are under review.

Dr John Reader, Sareum's Chief Scientific Officer, commented: "We welcome the additional allowance from the Chinese Patent Office, building on the recent approval of patents protecting the molecular structure of SDC-1801 in all major territories. This patent, covering various crystal forms, complements our existing molecular structure patents and extends the lifecycle of our patent estate. Combined with the encouraging data from the Phase 1a trial, this strengthened IP position gives us greater confidence as we look to advance SDC-1801 through clinical development, aiming to address unmet medical needs in various autoimmune diseases."

- Ends -

For further information, please contact: 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com